Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21419219 | 0.78 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL18125590 | 0.78 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL22402385 | 0.76 | KDM4E (0.33) | L3MBTL1KDM4EMAPT | |
| SCHEMBL7914425 | 0.72 | CCR1 (0.42) | DDB1CRBNPIK3CBCYP2A6KDM4E | |
| SCHEMBL926083 | 0.71 | DDB1 (0.39) | DDB1CRBNPIK3CBCYP2A6 | |
| SCHEMBL22323347 | 0.71 | DDB1 (0.39) | DDB1CRBNPIK3CBCYP2A6KDM4E | |
| SCHEMBL15091312 | 0.71 | PIK3CB (0.44) | DDB1CRBNPIK3CBCYP2A6 | |
| SCHEMBL3754475 | 0.71 | DDB1 (0.39) | DDB1CRBNPIK3CBCYP2A6 | |
| SCHEMBL23660941 | 0.71 | TRPA1 (0.35) | L3MBTL1KCNH2HRH3KDM4EGAA | |
| SCHEMBL13101099 | 0.69 | DRD2 (0.36) | CRBNCCR4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-07-22 | — | — | US | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-07-05 | — | — | US | disclosed |
| US-20180170935-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-06-21 | — | — | US | disclosed |
| US-9908887-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908887-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160214985-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-07-28 | — | — | US | disclosed |
| US-9388173-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8906900-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170935-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | DDB1 2281/4885CRBN 967/4885CCR4 2551/4885 |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DDB1 1077/4885CRBN 523/4885CCR4 4520/4885 |
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | DDB1 4737/4885CRBN 4864/4885CCR4 3063/4885 |
| US-20160214985-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DDB1 1144/4885CRBN 509/4885CCR4 4509/4885 |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DDB1 1077/4885CRBN 523/4885CCR4 4520/4885 |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DDB1 1077/4885CRBN 523/4885CCR4 4520/4885 |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | DDB1 1858/4885CRBN 517/4885CCR4 4086/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | DDB1 2139/4885CRBN 2988/4885CCR4 4485/4885 |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DDB1 1077/4885CRBN 523/4885CCR4 4520/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | DDB1 3548/4885CRBN 3148/4885CCR4 3495/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | DDB1 2088/4885CRBN 2989/4885CCR4 4489/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | DDB1 1858/4885CRBN 517/4885CCR4 4086/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | DDB1 1858/4885CRBN 517/4885CCR4 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.